<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01462851</url>
  </required_header>
  <id_info>
    <org_study_id>B3941001</org_study_id>
    <nct_id>NCT01462851</nct_id>
  </id_info>
  <brief_title>A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized Investigator-And-Subject-Blind, Sponsor Open, Placebo Controlled Two-Part Study To Characterize The Pharmacokinetics And Pharmacodynamics Of Single Doses Of Pf-05297909 In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to observe the safety and concentrations of PF-05297909 and proteins
      in both blood and cerebrospinal fluid after a single dose of PF-05297909 in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma area under the curve last (AUClast) pharmacokinetic parameter</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apparent clearance (CL/F) pharmacokinetic parameter</measure>
    <time_frame>Day 0 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical potency of PF 05297909 for reduction in CSF levels of Abeta40, Abeta42, and/or AbetaX via estimation of the IC50 from a population PK/PD (PPK/PD) model</measure>
    <time_frame>Day 0 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma area under the curve infinity (AUCinf) pharmacokinetic parameter</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma half-life (t1/2) pharmacokinetic parameter</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma apparent volume of distribution (Vz/F) pharmacokinetic parameter</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF concentration summary by time point for PF 05297909.</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CSF levels of Abeta40</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CSF levels of Abeta42</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CSF levels of AbetaX</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CSF levels of sAPPalpha</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CSF levels of sAPPbeta.</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: CSF PKPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05297909 25 mg</intervention_name>
    <description>Single oral (PO) dose, PF-05297909 25 mg</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05297909 100 mg</intervention_name>
    <description>Single oral (PO) dose, PF-05297909 100 mg</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05297909 250 mg</intervention_name>
    <description>Single oral (PO) dose, PF-05297909 250 mg</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05297909 525 mg</intervention_name>
    <description>Single oral (PO) dose, PF-05297909 525 mg</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05297909 525 mg</intervention_name>
    <description>Single oral (PO) dose, 525 mg</description>
    <arm_group_label>Part 2: CSF PKPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Healthy adult volunteers: healthy male and/or female subjects of non child bearing
             potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no
             clinically relevant abnormalities identified by a detailed medical history, full
             physical examination, including blood pressure and heart rate measurement, 12 lead ECG
             and clinical laboratory tests.)

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3941001&amp;StudyName=A%20Study%20To%20Observe%20Safety%20And%20Concentrations%20Of%20PF-05297909%20And%20Proteins%20In%20Both%20Blood%20And%20Cerebrospinal%20Fluid%20After%20A%20Single%20Dose%20O</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2011</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteer</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

